Bearing in mind the high affinity of the developed [99mTc]Tc-PSMA-T4 for PSMA in vivo and its confirmed high diagnostic efficacy in patients with PCa metastases, we decided to use this new system, containing two linkers (L-Trp-4-Amc) connected with the Glu-CO-Lys pharmacophore and HYNIC for 99mTc chelation, to develop a new ligand intended for radiolabeling with radionuclides for therapy (i.e., 177Lu, 90Y, 47Sc, and 225Ac). This evidence concerns the gene FOLH1 and posterior cortical atrophy.